Novel molecular CT technique could revolutionize drug discovery

A team of University of California Los Angeles and California Institute of Technology in Pasadena researchers have developed a new molecular imaging technique that may speed up drug discovery and is being dubbed as “a new day for chemistry” by the scientific community.  

The technique is able to map the structure of small organic molecules, such as pharmaceuticals and hormones, with electron diffraction imaging that is commonly used to chart larger proteins, according to a report published Oct. 19 by Science Magazine.  

Until now, x-ray crystallography and nuclear magnetic resonance spectroscopy have been the sole options to determine chemical structures. Utilizing electron diffraction, the new technique sends an electron beam through a crystal and—as in x-ray crystallography—determines a molecules structure from diffraction patterns, according to the article. 

For the study, researchers rotating the crystal and tracking how the diffraction pattern changed. They ultimately ended up getting an image that looked more like a molecular CT scan and enabled them to get structures from crystals one-billionth the size of those needed for x-ray crystallography. The research was published online Oct. 16 in ChemRxiv.  

See Science Magazine’s entire article below.  

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.